MedicineMaps

[{"result":"Decrease","duration":"100","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","stat_test":"t-test","is_hypothetical":"false","measure":"test","condition":"Neurofibromatosis type I","priority":"Primary","sample_size":1000,"experiment":"Positive","age_min":10,"dose_max":100,"uuid":"b5ba15d9-0b5f-46d6-9554-7d671435eaad","dose_min":10,"p_value":0.01,"age_max":40,"intervention":"lovastatin","outcome":"memory","type":"INHIBITS"},{"result":"Increase","stat_test":"t-test","is_hypothetical":"false","measure":"WRAML-2 Symbolic Memory","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"0daab89f-57dd-4b8b-9c98-0534a38c0946","p_value":0.03,"intervention":"lovastatin","outcome":"memory","type":"EXCITES"},{"result":"Increase","is_hypothetical":"false","stat_test":"t-test","measure":"WRAML-2 Design Memory","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"9dc1feb2-0293-47aa-9510-9d8a4a8a6431","p_value":0.005,"intervention":"lovastatin","outcome":"memory","type":"EXCITES"},{"result":"Increase","is_hypothetical":"false","stat_test":"t-test","measure":"WRAML-2 Story Memory","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"bb57b7e0-a366-4f18-b21e-bddedcde1565","p_value":0.03,"intervention":"lovastatin","outcome":"memory","type":"EXCITES"},{"result":"Decrease","stat_test":"within-participant repeated measures mixed-effects ordinary least-squares model","is_hypothetical":"false","measure":"resting state functional connectivity (RSFC) vMPFC","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"75ea6912-8f86-42b9-b55c-954af019708f","p_value":0.0003,"intervention":"lovastatin","outcome":"functional connectivity","type":"INHIBITS"},{"result":"Decrease","stat_test":"within-participant repeated measures mixed-effects ordinary least-squares model","is_hypothetical":"false","measure":"resting state functional connectivity (RSFC) TempP","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"c5d1513e-5a1e-46e1-a425-bd3e32f92dab","p_value":0.002,"intervention":"lovastatin","outcome":"functional connectivity","type":"INHIBITS"},{"result":"Decrease","stat_test":"within-participant repeated measures mixed-effects ordinary least-squares model","is_hypothetical":"false","measure":"resting state functional connectivity (RSFC) Rsp","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"fcf88d94-7c64-4ef9-b51f-416786399a8b","p_value":0.0001,"intervention":"lovastatin","outcome":"functional connectivity","type":"INHIBITS"},{"result":"Increase","stat_test":"within-participant repeated measures mixed-effects ordinary least-squares model","is_hypothetical":"false","measure":"resting state functional connectivity (RSFC) PCC","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"a3a76c2f-037a-40ee-8bd9-f80317c98a8b","p_value":0.0001,"intervention":"lovastatin","outcome":"functional connectivity","type":"EXCITES"},{"result":"Decrease","stat_test":"within-participant repeated measures mixed-effects ordinary least-squares model","is_hypothetical":"false","measure":"resting state functional connectivity (RSFC) PCC","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"09a55cfa-31d5-4fa6-b2de-2c09764e26ca","p_value":0.004,"intervention":"lovastatin","outcome":"functional connectivity","type":"INHIBITS"},{"result":"Increase","stat_test":"within-participant repeated measures mixed-effects ordinary least-squares model","is_hypothetical":"false","measure":"resting state functional connectivity (RSFC) dMPFC","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"a1144db1-bf98-4f46-88ce-94edcc55e052","p_value":0.0001,"intervention":"lovastatin","outcome":"functional connectivity","type":"EXCITES"},{"result":"Decrease","stat_test":"within-participant repeated measures mixed-effects ordinary least-squares model","is_hypothetical":"false","measure":"resting state functional connectivity (RSFC) dMPFC","condition":"Neurofibromatosis type I","sample_size":7,"age_min":10,"dose_max":40,"dose_min":20,"age_max":15,"duration":"84","paper_uuid":"98be639c-15ad-4221-acf0-8b416e32209d","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalation approach","uuid":"f7bcdd07-84e7-4726-8857-19a62c218c45","p_value":0.0001,"intervention":"lovastatin","outcome":"functional connectivity","type":"INHIBITS"}]